Acadian Asset Management
SRRA

Acadian Asset Management’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Acadian Asset Management’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,668
Closed -$79K – 1888
2021
Q4 		$79K Buy
+3,668
New +$80.8K ﹤0.01% 1420
2020
Q1 		– Sell
-34,290
Closed -$470K – 1996
2019
Q4 		$470K Buy
34,290
+11,809
+53% +$154K ﹤0.01% 1094
2019
Q3 		$351K Hold
22,481
– – ﹤0.01% 1179
2019
Q2 		$504K Buy
22,481
+10,319
+85% +$500K ﹤0.01% 1018
2019
Q1 		$831K Buy
12,162
+1,984
+19% +$127K ﹤0.01% 955
2018
Q4 		$538K Buy
10,178
+519
+5% +$33.1K ﹤0.01% 882
2018
Q3 		$656K Buy
9,659
+1,768
+22% +$160K ﹤0.01% 827
2018
Q2 		$934K Buy
7,891
+4,819
+157% +$484K ﹤0.01% 744
2018
Q1 		$254K Buy
3,072
+2,261
+279% +$256K ﹤0.01% 1008
2017
Q4 		$121K Buy
811
+429
+112% +$41.2K ﹤0.01% 1051
2017
Q3 		$24K Buy
382
+18
+5% +$1.06K ﹤0.01% 1201
2017
Q2 		$17K Buy
364
+16
+5% +$817 ﹤0.01% 1279
2017
Q1 		$21K Buy
+348
New +$20.2K ﹤0.01% 1365
2016
Q4 		– Sell
-220
Closed -$16K – 1814
2016
Q3 		$16K Sell
220
-101
-31% -$7.8K ﹤0.01% 1179
2016
Q2 		$26K Sell
321
-3
-0.9% -$572 ﹤0.01% 1123
2016
Q1 		$87K Buy
+324
New +$103K ﹤0.01% 1052

Other funds holding SRRA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management's SRRA Position: Q1 2022 in Review

Acadian Asset Management sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q1 2022, closing a stake of 3,668 shares — an estimated $79K sold.

Acadian Asset Management first reported a position in SRRA in Q1 2016 and held it in 16 quarters. The position peaked at $934K in Q2 2018. 75 funds tracked by Wall St. Rank hold SRRA as of Q1 2022.

  • Acadian Asset Management reported no remaining Sierra Oncology, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Acadian Asset Management sold 3,668 Sierra Oncology, Inc. Common Stock shares in Q1 2022, an estimated $79K.
  • Acadian Asset Management first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2016 and held it in 16 quarters.
  • Acadian Asset Management's Sierra Oncology, Inc. Common Stock position peaked at $934K in Q2 2018.
  • 75 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q1 2022.

Based on Acadian Asset Management's 13F filing for Q1 2022, filed 12 May 2022.